US 12,459,958 B2
Tricyclic compounds as HPK1 inhibitor and the use thereof
Jing Li, Beijing (CN); Zhiwei Wang, Beijing (CN); and Sanjia Xu, Beijing (CN)
Assigned to BeOne Medicines I GmbH, Basel (CH)
Appl. No. 17/627,885
Filed by BEIGENE, LTD., Grand Cayman (KY)
PCT Filed Jul. 17, 2020, PCT No. PCT/CN2020/102647
§ 371(c)(1), (2) Date Jan. 18, 2022,
PCT Pub. No. WO2021/013083, PCT Pub. Date Jan. 28, 2021.
Claims priority of application No. PCT/CN2019/096850 (WO), filed on Jul. 19, 2019.
Prior Publication US 2022/0267354 A1, Aug. 25, 2022
Int. Cl. C07D 519/00 (2006.01); A61P 35/00 (2006.01)
CPC C07D 519/00 (2013.01) [A61P 35/00 (2018.01)] 14 Claims
 
1. A compound of Formula (I)

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof,
wherein
X1 is CH or N;
X2 is N;
R1 and R2 are each hydrogen
n is 0;
R3 is —CONR3aR3b,
R4, at each of its occurrences, is independently halogen or —C1-8alkyl,
R3a and R3b are each independently hydrogen or —C1-8alkyl, said —C1-8 alkyl is optionally substituted with at least one substituent R3e, wherein R3e is selected from —OR3f or heterocyclyl, wherein the heterocyclyl is a 5-, 6- or 7-membered heterocyclyl comprising 1 heteroatom selected from nitrogen or oxygen; or
R3a and R3b, together with the atom(s) to which they are attached, form a 3- to 12-membered ring, said ring comprising 0, 1 or 2 additional heteroatom(s) independently selected from nitrogen and oxygen as ring member(s), said ring is optionally substituted with at least one substituent R3e, wherein R3e is each independently selected from oxo, —C1-8alkyl, —OR3f, —NR3fR3g or heterocyclyl, said —C1-8alkyl or heterocyclyl is optionally substituted by at least one halogen;
R3f and R3g are each independently hydrogen or —C1-8alkyl;
L1 is a single bond
R6 is —C1-8alkyl,
p is 0;
X3 and X4 are each CH2;
L2 is a single bond;
L3 is CH2;
R51 is hydrogen or —C1-8alkyl; and
m is 0.